3/25/2015 - 11:50 AM EST - Acasti Pharma Inc. : announced that the Chinese Patent Office has granted Acasti a composition and use patent. The Patent (ZL 201080059930.4), which is valid until 2030, relates to concentrated therapeutic phospholipid omega-3 compositions and covers methods for treating or preventing diseases associated with cardiovascular diseases, metabolic syndrome, inflammation, neurodevelopmental diseases, and neurodegenerative diseases. Acasti Pharma Inc.
shares V.APO are trading unchanged at $0.60.
